As Debbie Crawford said in Q4 call "we expect to report a net loss for the first quarter of 2012 due to the seasonality of prescription demand, increases in selling expenses associated with the addition of 40 new sales representatives, payment of the $4 million milestone for FDA acceptance of the UCERIS NDA, and higher R&D expenses associated with the UCERIS Phase IIIb study.". I think revenues are the same or slightly less than last quarter, probably around 42M, but high expenses can put down EPS; the real sales growth in the second half of year but we will see in a few hours.
The $4 million milestone was paid in SNTS stock. So, the cash is still on hand and COSMO chose payment in stock vs. cash. They were very smart, getting those shares just below $4.50. With SNTS, I agree, things are developing positively to lead to a super 2012 through each incremental quarter. UCERIS PDUFA and Rhucin Phase 3 results this Fall will move the stock even higher. JMO
Buy all dips (if and when you can) on a stock that is marching higher (SNTS). GLTA longs tonight!!